Article Text

Download PDFPDF
Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease
  1. Serdal Ugurlu1,
  2. Didar Ucar2,
  3. Emire Seyahi1,
  4. Gulen Hatemi1,
  5. Sebahattin Yurdakul1
  1. 1Department of Rheumatology, Cerrahpaşa Medical Faculty, University of Istanbul, Istanbul, Turkey
  2. 2Department of Ophthalmology, Cerrahpaşa Medical Faculty, University of Istanbul, Istanbul, Turkey
  1. Correspondence to Serdal Ugurlu, Department of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, 34098 Cerrahpasa-Fatih/Istanbul, Turkey; serdalugurlu{at}

Statistics from

Behçet's syndrome (BS) causes panuveitis and retinal vasculitis in about 50% of patients. Despite intensive treatment, up to 20% of patients may lose useful vision.1 Treatment consists of corticosteroids, immunosuppressive agents such as azathioprine (AZA) and ciclosporin A (CycA),1 and biological agents such as interferon-α (IFN) and antitumour necrosis factor agents.2 ,3 We describe a patient with juvenile BS whose refractory eye disease was treated successfully with canakinumab, a fully human anti-interleukin-1β antibody. Figure 1 shows the different treatment regimes used during the follow-up period.

Figure 1

Different treatment regimes and eye flares during the follow-up period.

A 16-year-old girl was diagnosed with BS at the age of 9 years because …

View Full Text


  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.